Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sankyo granted option for second-generation gluconeogenesis inhibitor for type 2 diabetes

Nov. 7, 2002

Atrix licenses leuprolide acetate products to EmerGen for endometriosis

Nov. 6, 2002

Series of glucocorticoid antagonists under study at Abbott

Nov. 6, 2002

New PDE3B inhibitors prepared and tested at Icos

Nov. 6, 2002

Pravachol approved for use in pediatric patients

Nov. 5, 2002

Replagal E.U. labeling expanded to include treatment of females

Nov. 5, 2002

Novartis to sell Leucomax rights to Schering-Plough

Nov. 5, 2002

Ferring and Johnson & Johnson to develop new generation of type 2 diabetes drugs

Nov. 5, 2002

Series of SGLT-2 inhibitors designed by Kissei

Nov. 4, 2002

Novel PARP inhibitors and their use in inflammatory disorders reported by Yamanouchi

Nov. 4, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...